Pepdox
Studies
Peptides
Calculator
Reframing polycystic ovary syndrome as a complication of obesity: the evolving role of incretin-based therapies. | Pepdox
Home
/
Search
/
PMID 40888044
Reframing polycystic ovary syndrome as a complication of obesity: the evolving role of incretin-based therapies.
Expert review of endocrinology & metabolism
2025
PMID: 40888044
View on PubMed
DOI: 10.1080/17446651.2025.2554668
Semaglutide
Tirzepatide
Authors
Jensterle, Mojca; Janez, Andrej
Keywords
Polycystic ovary syndrome
clinical obesity
incretin-based therapies
insulin resistance
liraglutide
reproductive outcomes
semaglutide
tirzepatide